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Abstract: Permanent hypoparathyroidism is the most 
common long-term complication after thyroidectomy. We 
evaluated whether iPTH concentrations on the first post-
operative day may be a good predictor of this complica-
tion.
Patients undergoing thyroidectomy in our Unit between 
January 2017 and February 2018 who developed postsur-
gical hypoparathyroidism were analysed. According to 
iPTH values on the first postoperative day and on the basis 
of the detection threshold of the iPTH test used, patients 
were divided into 2 groups: Group A (iPTH < 6.3 pg/mL, 
undetectable), Group B (iPTH ≥ 6.3 pg/mL).
Seventy-five patients were included in this study: 64 
in Group A and 11 in Group B. Permanent hypoparathy-
roidism occurred in 14 (21.88%) patients in Group A, while 
none developed this complication in Group B. When iPTH 
was < 6.3 pg/mL, the sensitivity for the prediction of per-
manent hypoparathyroidism was 100%, the specificity 
was 18.03%, the positive predictive value was 21.88% and 
the negative predictive value was 100%.
No patient with iPTH ≥ 6.3 pg/mL on the first postoper-
ative day developed permanent hypoparathyroidism. On 
the other hand, iPTH concentrations < 6.3 pg/mL have not 
proved to be a strong predictor of this condition. However, 
this cut-off value can be useful to identify patients at risk 
of developing this complication. 
Keywords: Permanent hypoparathyroidism; Total thyroid-
ectomy; Intact parathyroid hormone; Undetectable iPTH
1  Introduction
Total thyroidectomy (TT) is the most widely surgical pro-
cedure performed in endocrine surgery, for both benign 
and malignant thyroid diseases. 
Hypoparathyroidism (HPP) is a common complication 
after TT [1-9]. This condition is characterized by decreased 
values of circulating parathyroid hormone leading to 
hypocalcemia and slightly higher phosphate levels. 
Hypocalcemia can cause symptoms ranging from 
numbness of the face and hands to tetany, convulsions 
and suffocation (caused by laryngeal and diaphragmatic 
spasms). Moreover, manifestations of chronic hypocalce-
mia include some severe conditions, such as nephrocalci-
nosis, kidney stones, chronic kidney disease, myocardial 
dysfunction, basal ganglia calcifications, cataracts and 
dental abnormalities [10-15]. 
In case of HPP, the main purpose of treatment is to 
maintain normal blood calcium levels. Medical therapy of 
hypocalcemia consists in the administration of calcium 
and vitamin D [16]. 
Although HPP after TT reverses spontaneously within 
a few months in most cases, in a few patients, it can 
persist for more than 1 year [4]. In this case this condition 
has to be considered permanent and, to avoid the subtle 
but potentially lethal complications of chronic hypocalce-
*Corresponding author: Gian Luigi Canu, Department of Surgical 
Sciences, University of Cagliari, “Policlinico Universitario Duilio 
Casula”, 09042, Monserrato (CA), Italy, Tel. +393408320129, Email: 
gianlu_5@hotmail.it
Fabio Medas, Alessandro Longheu, Enrico Erdas, Pietro Giorgio 
Calò, Department of Surgical Sciences, University of Cagliari, “Polic-
linico Universitario Duilio Casula”, 09042, Monserrato (CA), Italy
Francesco Boi, Department of Medical Sciences, University of Cag-
liari, Endocrinology Unit,  “Policlinico Universitario Duilio Casula”, 
09042, Monserrato (CA), Italy 
Giovanni Docimo, Department of General Surgery, General and En-
docrine Surgical Unit, Second University of Naples, 80131, Naples, 
Italy
 Open Access. © 2019 Gian Luigi Canu et al.,  published by De Gruyter.  This work is licensed under the Creative Commons Attribution 4.0 
License. Unauthenticated
Download Date | 7/13/19 7:21 PM
438   Gian Luigi Canu et al.
mia, long-term therapy and careful follow-up are manda-
tory. However, long-term calcium supplementation can 
also cause side effects, such as gastrointestinal reactions, 
myocardial infarction and urinary calculi [17].
The incidence of transient and permanent hypopar-
athyroidism is 6.9–46% and 0-10% respectively [2, 5, 18].
Costs to society in terms of increased postoperative 
stay, sick leave, medical treatments and surveillance, with 
periodic laboratory testing, are considerable. Moreover, 
permanent HPP is an important cause of medical litiga-
tion.
Currently, there are no reliable immediate postoper-
ative biochemical parameters which allow the identifi-
cation of those patients with postsurgical HPP who will 
develop permanent HPP [19]. In order to ensure patients 
the best follow-up, it would be very useful to be able to 
predict the risk of permanent HPP at an early stage after 
surgery. To date, there is still no consensus about the 
correlation between postoperative intact parathyroid 
hormone (iPTH) values and the development of this con-
dition [20-34]. The aim of the present study was to investi-
gate this topic. In particular, we evaluated whether iPTH 
concentrations on the first postoperative may be a good 
predictor of permanent HPP.
2  Methods
This is a retrospective study on patients who underwent 
thyroidectomy in our Unit of General and Endocrine 
Surgery (University of Cagliari) between January 2017 and 
February 2018.
Only patients with postsurgical HPP after TT were 
considered. Among these, those simultaneously submit-
ted to lateral and/or central neck dissection were included 
in this study, while those who simultaneously underwent 
parathyroidectomy or parathyroid autotransplantation 
were excluded. 
All operations were performed under general anaes-
thesia. Lateral and/or central neck dissection was per-
formed in patients with preoperative or intraoperative 
suspicion of lymph node metastases.  Recurrent laryn-
geal nerves and parathyroid glands were systematically 
searched and identified. Intraoperative nerve monitor-
ing (IONM) was routinely used in order to facilitate nerve 
identification and to confirm its functional integrity. Hae-
mostasis was mainly achieved by means of energy-based 
devices. One or two closed suction drains were placed 
below the strap muscles and removed when the secretion 
volume was less than 20 ml over 24 hours. The cervical 
linea alba and platysma were sutured with absorbable 
sutures and skin was closed by a continuous intradermal 
suture. 
Demographic data (sex, age), information on surgical 
procedure (extent of surgery) and histopathological find-
ings were recorded. 
Serum calcium and iPTH levels were assayed preop-
eratively and on the first and second postoperative days. 
Postsurgical HPP was defined as iPTH < 10 pg/mL on the 
second postoperative day (normal range = 10-65 pg/mL). 
All patients with postsurgical HPP, even if asymptomatic, 
received treatment with calcium carbonate (1–3 g/day) 
and calcitriol (0.5–1.5 μg /day). In case of severe hypoc-
alcemia, intravenous calcium gluconate was used.
According to iPTH values on the first postoperative 
day and on the basis of the detection threshold of the iPTH 
test used, patients were divided into 2 groups: those with 
iPTH < 6.3 pg/mL (undetectable) were included in Group 
A, those with iPTH ≥ 6.3 pg/mL in Group B.
Permanent HPP was defined as iPTH concentrations 
below the normal range for more than 12 months.
Intact parathyroid hormone was measured with 
ADVIA Centaur® XPT Immunoassay  Systems (Siemens 
Healthcare Diagnostics, Inc.).
Statistical analyses were performed with MedCalc® 
18.0.2. Fisher exact test was used for categorical variables 
and t-test for continuous variables. Sensitivity, specificity, 
positive predictive value (PPV), and negative predictive 
value (NPV) were calculated. P values < 0.05 were consid-
ered statistically significant.
Ethical approval: The research related to human use has 
been complied with all the relevant national regulations, 
institutional policies and in accordance the tenets of 
the Helsinki Declaration, and has been approved by the 
authors' institutional review board or equivalent commit-
tee.
Informed consent: Informed consent has been obtained 
from all individuals included in this study.
3  Results
A total of 75 patients were included in this study. There 
were 16 (21.33%) males and 59 (78.67%) females, with 
a mean age of 49.25 ± 16.77 years old. Sixty-six (88%) 
patients underwent total thyroidectomy, 4 (5.33%) total 
thyroidectomy with ipsilateral central neck dissection, 
3 (4%) total thyroidectomy with central neck dissection 
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and 2 (2.67%) total thyroidectomy with central and lateral 
neck dissection. Mean thyroid weight was 58.44 ± 61.08 
g. Histopathological diagnosis was benign disease in 43 
(57.33%) patients and malignancy in 32 (42.67%).
Of the 75 patients, 64 were included in Group A and 
11 in Group B.
In Group A, there were 15 (23.44%) males and 49 
(76.56%) females, with a mean age of 47.91 ± 16.99 years 
old. Fifty-six (87.50%) patients underwent total thyroid-
ectomy, 3 (4.69%) total thyroidectomy with ipsilateral 
central neck dissection, 3 (4.69%) total thyroidectomy 
with central neck dissection and 2 (3.12%) total thyroid-
ectomy with central and lateral neck dissection. Mean 
thyroid weight was 59.14 ± 63.79 g. Histopathological 
diagnosis was benign disease in 36 (56.25%) patients and 
malignancy in 28 (43.75%).
In Group B, there were 1 (9.09%) male and 10 (99.91%) 
females, with a mean age of 57.09 ± 13.55 years old. Ten 
(90.91%) patients underwent total thyroidectomy and 1 
(9.09%) total thyroidectomy with ipsilateral central neck 
dissection. Mean thyroid weight was 54.36 ± 44.11 g. His-
topathological diagnosis was benign disease in 7 (63.64%) 
patients and malignancy in 4 (36.36%).
Demographic data, extent of surgery and histopatho-
logical findings were comparable between the 2 groups.
Permanent HPP occurred in 14 (21.88%) patients 
in Group A, while none developed this complication in 
Group B (this difference was not statistically significant).
When iPTH levels were < 6.3 pg/mL on the first post-
operative day the sensitivity for the prediction of perma-
nent HPP was 100%, the specificity was 18.03%, the PPV 
was 21.88% and the NPV was 100%.
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Age (mean ± SD) 49.25 ± 16.77 47.91 ± 16.99 57.09 ± 13.55 NS
Extent of surgery
   - TT
   - TT + ICND
   - TT + CND


















   (mean ± SD)
58.44 ± 61.08 59.14 ± 63.79 54.36 ± 44.11 NS
Histological diagnosis
   - Benign disease








TT, total thyroidectomy; ICND, ipsilateral central neck dissection; CND, central neck dissection; LND, lateral neck dissection









   hypoparathyroidism
14 (18.67%) 14 (21.88%) 0 NS
Table 3: Correlation between iPTH levels < 6.3 pg/mL on the first 





PPV, positive predictive value; NPV, negative predictive value
Unauthenticated
Download Date | 7/13/19 7:21 PM
440   Gian Luigi Canu et al.
4  Discussion
Despite progress in surgical technique and even in the 
most experienced hands, postsurgical HPP remains a 
challenging problem. Permanent HPP is the most common 
long-term complication after TT [1-9]. 
During surgery parathyroid glands can be damaged 
due to various mechanisms: thermal or mechanical 
stress, vascular injury (interrupted blood flow or impaired 
venous efflux) and involuntary removal [7, 31, 35-37]. 
Some factors have been associated with an increased 
risk of developing postsurgical HPP, such as female 
gender, thyroid cancer, Graves’ disease, autoimmune thy-
roiditis and central neck dissection [1, 31, 35-45].
To date, there is still no consensus about the useful-
ness of postoperative iPTH levels to predict permanent 
HPP [20-34]. We evaluated whether iPTH values on the 
first postoperative day may be a good predictor of this 
complication. In the literature, we found some similar 
studies.
Almquist M. et al [29] stated that iPTH levels measured 
on the first postoperative day are associated with the risk 
of permanent HPP. In their experience, of 10 patients with 
permanent HPP, 8 had iPTH < 6.6 pg/mL and 2 had iPTH 
between 6.6 and 15 pg/mL. However, among the patients 
with iPTH values < 6.6 pg/mL the rate of this complication 
was only 19.2%.
In the study of Julián M.T. et al [30], iPTH concentra-
tions ≤ 5.8 pg/mL on postoperative day 1 had 100% sensi-
tivity, 81.5% specificity and 30% positive predictive value 
for permanent HPP. Conversely, iPTH levels > 5.8 pg/mL 
were correlated with normal parathyroid function in the 
long term.
In the experience of Wang J.B. et al [31], iPTH concen-
trations < 7 pg/mL on postoperative day 1 had sensitivity 
and negative predictive value of 100% for permanent HPP, 
but poor specificity and positive predictive value (70.19% 
and 8.63% respectively). 
Kim H. et al [32] stated that the safest cut-off value of 
iPTH on the first postoperative day for the prediction of 
permanent HPP is 9.65 pg/mL (70.9% sensitivity and 100% 
specificity). None of the patients with iPTH > 9.65 pg/mL 
developed this complication. 
In the study of Wang W. et al [33], iPTH levels ≤ 3.14 
pg/mL on postoperative day 1 had 100% sensitivity for 
the prediction of permanent HPP, 95% specificity, 66.67% 
positive predictive value and 100% negative predictive 
value. Therefore, these researchers stated that iPTH levels 
> 3.14 pg/mL are great in assessing the absence of this 
complication.  
Calvo Espino P. et al [34] found that a cut-off value of 
iPTH  on the first postoperative day of 5 pg/mL has 95% 
sensitivity, 77% specificity, 21.6% positive predictive value 
and 99.6% negative predictive value for the prediction 
of permanent HPP. Therefore, they stated that this iPTH 
level, because of its high negative predictive value, is a 
useful predictor of permanent HPP. 
In our study, we included only patients with postsur-
gical HPP, diagnosed on the basis of iPTH concentrations 
on the second postoperative day. According to our expe-
rience and that of other researchers, we consider iPTH 
values on postoperative day 2, rather than on postopera-
tive day 1, more accurate in assessing the true functional 
state of parathyroid glands after TT. Among the patients 
considered, iPTH levels on the first postoperative day have 
been analysed. When iPTH concentrations were < 6.3 pg/
mL, the sensitivity and the negative predictive value for 
permanent HPP were high (both 100%), but the specific-
ity and the positive predictive value were poor, 18.03% 
and 21.88% respectively. It is important to underline that 
no patient with iPTH values ≥ 6.3 pg/mL developed this 
complication. As already explained above, in our study, 
the cut-off value was established on the basis of the detec-
tion threshold of the iPTH test used. Among the 2 groups 
obtained in this way, no statistically significant difference 
was found in terms of demographic data, extent of surgery 
and histopathological findings.
In light of the results obtained by our and the other 
studies analysed, to date, a cut-off value of iPTH on the 
first postoperative day accurate enough for the predic-
tion of permanent HPP has not yet been identified. Thus, 
further larger and possibly multicenter studies are needed 
to better investigate this topic.
5  Conclusions
No patient with iPTH levels ≥ 6.3 pg/mL on the first 
postoperative day after TT developed permanent HPP. On 
the other hand, iPTH concentrations < 6.3 pg/mL have 
not proved to be a strong predictor of this condition (PPV, 
21.88%; specificity, 18.03%). However, this cut-off value 
can be useful to identify patients at risk of developing this 
complication (sensitivity, 100%), who require a careful 
follow-up. 
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